European Academy of Allergy and Clinical Immunology

Invest in Our Planet: EAACI in Support of Sustainable Health

Retrieved on: 
Saturday, April 22, 2023
Allergy, Telehealth, Communication, Human, Asthma, Health Canada Sodium Working Group, Environmental science, United States Secretary of the Air Force, Atmosphere, Survival, Environmental health, EAACI, Research, European Academy of Allergy and Clinical Immunology, United States Senate Democratic Steering and Outreach Committee, Science, Organization, Plant, Working Group, Hospital, Climate change, Animal, Soil, Patient, Laboratory, Water, Knowledge, Health, Transport, Family, WG, Nursing, Renewable energy, ROC

This year's theme "Invest in Our Planet" emphasizes the need for global investment in sustainable solutions to protect our planet for the health and survival of people and animals.

Key Points: 
  • This year's theme "Invest in Our Planet" emphasizes the need for global investment in sustainable solutions to protect our planet for the health and survival of people and animals.
  • The EAACI family is committed to promoting sustainable practices and supporting investment in research and development for sustainable solutions.
  • Some other sustainable practices promoted directly within EAACI include:
    Reducing paper use and promoting digital communication in our events and activities.
  • "It is up to us to take action and invest in sustainable solutions for the benefit of current and future generations," stresses WG One Health chair Isabella Pali.

Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Monday, November 14, 2022
Marketing, TH1, RNA-Seq, Inflammation, Chemistry, EV, Seminal vesicles, Research, Chorionic gonadotropin beta, Risk, Inflammatory bowel disease, European Medicines Agency, IL-6, Allergy, TNF, Conference, Patient, IL-8, Arthritis, Cytokine, European Academy of Allergy and Clinical Immunology, CTA, T helper 17 cell, Development, FDA, COVID-19, Growth, Health care, EMA, Physician, Disease, Volunteering, Failure, Clinical trial, Atopic dermatitis, EVS, CMC, Administration, Poster, PASI, Psoriasis Area and Severity Index, Blood, Asthma, MHRA, Confidentiality, Congress, Pharmaceutical industry, Medical device, Dietary supplement, Dermatology, Venereology, Psoriasis

CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced its third quarter 2022 financial results and business highlights.

Key Points: 
  • Recruitment for the first three cohorts in the Phase 2 trial of EDP1815 in atopic dermatitis is complete.
  • Recruitment for the fourth cohort is ahead of schedule, with data expected in the second quarter of 2023.
  • In September 2022, Evelo presented a poster at the 2022 European Academy of Dermatology and Venereology (EADV) Congress.
  • In October 2022, Evelo presented two posters at the 2022 Fall Clinical Dermatology Conference.

The Growing Prevalence Of Respiratory Allergies Will Propel The Car Air Purifier Market To More Than $2 Billion By 2026 - By The Business Research Company

Retrieved on: 
Thursday, November 24, 2022
Aerosol, Throat irritation, Filter (signal processing), Ion, EPA, Allergy, Headache, Nose, Volatile organic compound, Liver, Animal, Kidney, Xylene, Cancer, Human, Pollen, European Academy of Allergy and Clinical Immunology, Ozone, Atmosphere, Nausea, Eye, Organic compound, Growth, Central nervous system, Union, Dust, Incidence, Environmental remediation

Car air purifiers will be needed to protect people from contaminated outdoor air when traveling in cars.

Key Points: 
  • Car air purifiers will be needed to protect people from contaminated outdoor air when traveling in cars.
  • Thus, the increase in the incidence of respiratory allergies will bolster the demand for car air purifier market.
  • As per the car air purifier market analysis , the introduction of antimicrobial filters is gaining popularity in the car air purifier market.
  • Safety concerns with car air purifiers are expected to be a limiting factor for the growth of the car air purifier market during the forecast period, according to our car air purifier outlook.

Cabaletta Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 10, 2022
IND, A5, Partnership, Research, Risk, SLE, MuSK protein, Company, Form 10-K, Lupus, Conference, Public health, Security (finance), Industry, Immunoglobulin therapy, Review, Rheumatoid arthritis, Marketing, European Academy of Allergy and Clinical Immunology, Toxic shock syndrome, Pemphigus, Nature Medicine, Cell, Degenerative disease, Scleroderma, Gene, U.S. Securities and Exchange Commission, Myasthenia gravis, Cancer, Patient, Autoimmunity, Drug discovery, Cyclophosphamide, Private Securities Litigation Reform Act, Myositis, Annual report, CARTA, MG, Clinical trial, Journal of the European Academy of Dermatology and Venereology, CD19, Congress, FDA, GLOBE, Investment, MPV, European Society for Medical Oncology, CAR, Safety, ODD, Immune system, Pharmaceutical industry, Vaccine, COVID-19, Cabaletta, Venereology, Dermatology

PHILADELPHIA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today reported financial results for the third quarter ended September 30, 2022, and provided a business update.

Key Points: 
  • PHILADELPHIA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today reported financial results for the third quarter ended September 30, 2022, and provided a business update.
  • First-in-human trial to initiate in the fourth quarter of 2022: Cabaletta remains on track to initiate the MusCAARTes trial for MuSK-CAART in the fourth quarter of 2022.
  • Cabaletta will participate in the upcoming 5th Annual Evercore ISI HealthCONx Conference, which is being held virtually from November 29 December 1, 2022.
  • All information in this press release is as of the date of the release, and Cabaletta undertakes no duty to update this information unless required by law.

Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 9, 2022
IND, B cell, Research, G&A, Therapy, PD-1, Survival, Company, Form 10-K, Program, Cell, ILT4, CMC, Review, Forward-looking statement, European Academy of Management, Omalizumab, Hives, Knowledge, Environment, Contingency (philosophy), UAS7, European Academy of Allergy and Clinical Immunology, Cancer, Patient, Cold urticaria, COVID-19, EOE, Metabolic pathway, Private Securities Litigation Reform Act, Risk, Itchy, Eosinophilic esophagitis, Hypersensitivity, EAACI, Annual report, Allergy, R, Rockefeller University, Antibody, Gilead Sciences, Myelocyte, Skin, Trial of the century, GLOBE, CSU, Intellectual property, SD, Consultant, NASDAQ, Goal, KIT, Drug development, D, Ovarian cancer, Prurigo nodularis, Immune system, Judgement, SRS, Inflammation, CD27, Pharmaceutical industry, Vaccine, Palladium, Security (finance)

HAMPTON, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Key Points: 
  • HAMPTON, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
  • Barzolvolimab is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity.
  • Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2022 were $323.5 million compared to $356.8 million as of June 30, 2022.
  • Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at September 30, 2022 are sufficient to meet estimated working capital requirements and fund planned operations through 2025.

Astria Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, November 10, 2022
Research, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, ACAAI, Capital structure, Review, ATM, Forward-looking statement, Investment, European Academy of Allergy and Clinical Immunology, Plasma kallikrein, Asthma, Food, Hereditary angioedema, FDA, Simulation, Risk, Drug discovery, HAE, Half-life, Therapy, SEC, Annual report, NASDAQ, Goal, Safety, Pharmacy, Time, Pharmacokinetics, Drug, Company, D, Human, Research, Patient, American College of Allergy, Asthma and Immunology, Allergy, COVID-19, Food and Drug Administration Amendments Act of 2007, American College, Pharmaceutical industry, Medical device, Reinsurance, Air cargo, Asteria

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
  • We are on track to report preliminary results from our Phase 1a trial of STAR-0215 by the end of this year.
  • We believe the results from this trial will validate STAR-0215s differentiated best-in-class profile, said Jill C. Milne, Ph.D., Chief Executive Officer of Astria.
  • The Food and Drug Administration cleared Astrias Investigational New Drug application for STAR-0215 in July 2022.

Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress

Retrieved on: 
Saturday, September 10, 2022
U.S. Securities and Exchange Commission, Cyclophosphamide, Risk, Infrared spectroscopy correlation table, Industry, Cohort, Haemophilia, Immunoglobulin therapy, Degenerative disease, AES, Autoantibody, Real-time, Cell, Congress, ELISA, Pemphigus, MPV, Glomerulonephritis, Incidence, Cytokine release syndrome, Adult, A1, MuSK protein, Private Securities Litigation Reform Act, European Academy of Allergy and Clinical Immunology, Cytokine, Neurotoxicity, LinkedIn, CRS, Public health, GLOBE, CY, Safety, Annual report, Patient, Form 10-K, Pemphigus vulgaris, Biopsy, A4, Twitter, Security (finance), Pharmaceutical industry, Medical device, Coffee, Vaccine, A5, Venereology, Dermatology, Cabaletta, COVID-19

The data demonstrate:

Key Points: 
  • The data demonstrate:
    Doses up to 7.5 billion DSG3-CAART cells (cohort A5) were generally well tolerated, with no DLTs, and one grade 1 CRS.
  • The trial is currently being conducted across multiple clinical sites throughout the United States and is enrolling patients in the combination sub-study.
  • Cabalettas DesCAARTes Phase 1 trial is an open-label, dose escalation, multi-center study of DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV).
  • Cabaletta Bios headquarters are located in Philadelphia, PA. For more information, visit www.cabalettabio.com and follow us on LinkedIn and Twitter.

FDA and EMA Accept Regulatory Submission for Pfizer’s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata

Retrieved on: 
Friday, September 9, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Janus, European Medicines Agency, Janus kinase 3, Severity, EMA, NDA, Hair, NYSE, Autoimmune disease, New Drug Application, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Alopecia areata, Doctor of Philosophy, Pfizer, PFE, Hair loss, SALT, MAA, Food, Inflammation, JAK3, American Academy, Immunology, Inc., Patient, European Academy of Allergy and Clinical Immunology, FDA, Immune system, Population, Eyelash, United Kingdom, TEC, ALLEGRO, Face, Congress, Scalp, Marketing, Eyebrow, Alopecia totalis, Journal of the European Academy of Dermatology and Venereology, Pharmaceutical industry, Venereology, Dermatology

Alopecia areata affects approximately 6.8 million people in the U.S. and around 147 million people globally.

Key Points: 
  • Alopecia areata affects approximately 6.8 million people in the U.S. and around 147 million people globally.
  • Pfizer has also completed regulatory submissions for ritlecitinib in the United Kingdom, China and Japan, and expects decisions in 2023.
  • The randomized, placebo-controlled, double-blind ALLEGRO Phase 2b/3 study investigated ritlecitinib in patients 12 years of age and older with alopecia areata (n=718).
  • Alopecia areata is an autoimmune disease that has underlying immuno-inflammatory pathogenesis and targets hair follicles, which results in hair loss.

LEO Pharma presents new AdbryTM (tralokinumab-ldrm) safety data in moderate-to-severe atopic dermatitis at 31st EADV Congress

Retrieved on: 
Thursday, September 8, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, Tralokinumab, Allergy, AES, Hypersensitivity, Safety, AAD, Atopic dermatitis, American Academy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Conjunctivitis, DDI, Itch, Vitamin, Food, Drug, Skin, Upper respiratory tract infection, Headache, Dermatitis, LEO, Annual general meeting, Patient, Respiratory tract, Breast milk, Anaphylaxis, FDA, American Academy of Dermatology, Adult, Eczema herpeticum, Tell, TCS, Syringe, Cancer, Leo Pharma, European Academy of Allergy and Clinical Immunology, Pharmaceutical industry, Vaccine, Fair, Dietary supplement, Health insurance, Birth control, Venereology, Dermatology

LEO Pharma A/S, a global leader in medical dermatology, today announced new safety data for AdbryTM (tralokinumab-ldrm) for adult patients with moderate-to-severe atopic dermatitis (AD).

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today announced new safety data for AdbryTM (tralokinumab-ldrm) for adult patients with moderate-to-severe atopic dermatitis (AD).
  • These findings build on the long-term safety data presented at the American Academy of Dermatology (AAD) 2022 Annual Meeting, which demonstrated Adbry's consistent safety from the parent trials.
  • We recognize safety is paramount to patients and clinicians as they consider treatment options for moderate-to-severe atopic dermatitis, and we hope these results inspire continued confidence in Adbry.
  • Stop using ADBRY and tell your healthcare provider or get emergency help right away if you get any of the following symptoms:

ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Multiple Posters at the 31st Annual European Academy of Dermatology and Venereology (EADV) Congress

Retrieved on: 
Wednesday, September 7, 2022
NASDAQ, Immunoglobulin E, Itch, Sleep, Serum, Congress, POC, TARC, ASLN, GLOBE, Surround optical-fiber immunoassay, European Academy of Allergy and Clinical Immunology, Atopy, Atopic dermatitis, Biomarker, AD, AD1, Patient, LDH, Vaccine, Pharmaceutical industry, Venereology, Dermatology

Three posters are being presented as e-posters throughout the duration of the congress from September 7 to 10, 2022.

Key Points: 
  • Three posters are being presented as e-posters throughout the duration of the congress from September 7 to 10, 2022.
  • Collectively, the data being presented at EADV gives us great confidence to continue investigating eblaskaimabs role in AD and other indications in the future.
  • Signaling through the Type 2 receptor induces expression of a multitude of marker molecules, correlating with disease severity.
  • The poster shows results of patient samples from the proof-of-concept (PoC) trial of eblasakimab in adults with moderate-to-severe atopic dermatitis.